Prostate Cancer - PSA

Prostate Cancer - PSA

 

Prostate cancer is the most frequent malignant neoplasia in men and the second most common cause of cancer death among American men.

Epidemiology

  • Prevalence – 6th most common cancer in the world
  • Age – risk rises steeply with age
    • <50 years – low risk
    • 75% of cases occur in men ≥65 years

Risk Factors

  • Ethnicity – Black race has higher occurrence
  • Family history – 5-11 fold increase
  • Age – common malignancy in elderly males

Pathophysiology

  • Tumors are usually adenocarcinoma and depend on androgen for growth
  • Epithelial cells of prostate produce prostate specific antigen and acid phosphatase
    • Production increased with tumors
  • Most tumors develop in peripheral zone of prostate

Clinical Presentation

  • May have signs and symptoms of enlarged prostate – urgency, frequency of urination
  • Metastatic disease
    • Bone pain – pelvis, spine

Diagnosis

  • Laboratory testing
    • Prostate specific antigen (PSA)
  • Biopsy
    • Sonographically guided biopsy is current means of diagnosis
      • Tumors assigned Gleason score

Differential Diagnosis

  • Prostatitis
  • Benign prostatic hypertrophy

Disease Monitoring

  • Laboratory testing
    • Prostatic specific antigen (PSA)
  • Successful surgical resection should lead to concentrations <0.05 ng/mL
  • Radiation therapy may not result in levels this low
    • Subsequent rise is indicative of residual disease or metastasis

Disease Screening

  • PSA is the only tumor marker available that has been approved for use as a screening test for prostate cancer
  • Prostatic acid phosphatase has little value in screening for prostate cancer
  • Several forms of PSA are present in serum
    • A greater percentage of free PSA is found in patients with benign conditions of the prostate than in patients with prostate cancer
    • Approximately one-third of patients with PSA levels between 4.1-10.0 ng/mL will have prostate cancer detectable by biopsy within 1 year
Prostate Specific Antigen, Free Percentage
Probability of finding prostate cancer on needle biopsy by age in years in patients with total PSA concentrations of 4-10 ng/mL
% Free PSA ratio 50-59 60-69 70 or older
10% 49% 58% 65%
11-18% 27% 34% 41%
19-25% 18% 24% 30%
>25% 9% 12% 16%
The free percentage is calculated using the total and free PSA results
(Adapted with permission from Modular Analytics E170, 2005, 3)